Skip to main content
. 2022 Sep 9;13:975246. doi: 10.3389/fimmu.2022.975246

Figure 1.

Figure 1

Kaplan-Meier estimates of progression-free survival (PFS) and overall survival (OS): (A) PFS in all patients; (B) OS in all patients; (C) PFS in patients receiving combination therapy with Eastern Cooperative Oncology Group (ECOG) score 0-1 and no more than 2 lines of prior therapy; (D) OS in patients receiving combination therapy with ECOG score 0-1 and no more than 2 lines of prior therapy.